The stanford prostate cancer calculator: Development and external validation of online nomograms incorporating PIRADS scores to predict clinically significant prostate cancer.

[1]  A. Sidana,et al.  Racial disparity in the utilization of multiparametric MRI–ultrasound fusion biopsy for the detection of prostate cancer , 2020, Prostate Cancer and Prostatic Diseases.

[2]  James D. Murphy,et al.  Survival of African American and non‐Hispanic white men with prostate cancer in an equal‐access health care system , 2020, Cancer.

[3]  L. Marks,et al.  Magnetic Resonance Imaging Guided Biopsy to Evaluate Prostate Cancer Severity in African American Men , 2019 .

[4]  D. Margolis,et al.  Prostate Imaging Reporting and Data System Version 2.1: 2019 Update of Prostate Imaging Reporting and Data System Version 2. , 2019, European urology.

[5]  A. Stenzinger,et al.  Prediction of significant prostate cancer in biopsy-naïve men: Validation of a novel risk model combining MRI and clinical parameters and comparison to an ERSPC risk calculator and PI-RADS , 2019, PloS one.

[6]  Richard E. Fan,et al.  Applying the PRECISION approach in biopsy naïve and previously negative prostate biopsy patients. , 2019, Urologic oncology.

[7]  F. Montorsi,et al.  Structured Population-based Prostate-specific Antigen Screening for Prostate Cancer: The European Association of Urology Position in 2019. , 2019, European urology.

[8]  Audrey Renson,et al.  Predicting Benign Prostate Pathology on Magnetic Resonance Imaging/Ultrasound Fusion Biopsy in Men with a Prior Negative 12-core Systematic Biopsy: External Validation of a Prognostic Nomogram. , 2019, European urology focus.

[9]  Douglas K Owens,et al.  Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement , 2018, JAMA.

[10]  D. Margolis,et al.  MRI‐Targeted or Standard Biopsy for Prostate‐Cancer Diagnosis , 2018, The New England journal of medicine.

[11]  J. Weinreb,et al.  MRI-Ultrasound Fusion Targeted Biopsy of Prostate Imaging Reporting and Data System Version 2 Category 5 Lesions Found False-Positive at Multiparametric Prostate MRI. , 2018, AJR. American journal of roentgenology.

[12]  E. Messing,et al.  Multi‐institutional nomogram predicting benign prostate pathology on magnetic resonance/ultrasound fusion biopsy in men with a prior negative 12‐core systematic biopsy , 2018, Cancer.

[13]  A. Rosenkrantz,et al.  Prediction of Prostate Cancer Risk Among Men Undergoing Combined MRI-targeted and Systematic Biopsy Using Novel Pre-biopsy Nomograms That Incorporate MRI Findings. , 2017, Urology.

[14]  Richard E. Fan,et al.  Prostate Magnetic Resonance Imaging Interpretation Varies Substantially Across Radiologists. , 2017, European urology focus.

[15]  D. Moses,et al.  A multiparametric magnetic resonance imaging‐based risk model to determine the risk of significant prostate cancer prior to biopsy , 2017, BJU international.

[16]  M. Roethke,et al.  Combined Clinical Parameters and Multiparametric Magnetic Resonance Imaging for Advanced Risk Modeling of Prostate Cancer-Patient-tailored Risk Stratification Can Reduce Unnecessary Biopsies. , 2017, European urology.

[17]  P. Humphrey,et al.  Prostate zonal anatomy correlates with the detection of prostate cancer on multiparametric magnetic resonance imaging/ultrasound fusion-targeted biopsy in patients with a solitary PI-RADS v2-scored lesion. , 2017, Urologic oncology.

[18]  B. Hadaschik,et al.  The Value of PSA Density in Combination with PI‐RADS™ for the Accuracy of Prostate Cancer Prediction , 2017, The Journal of urology.

[19]  E. Messing,et al.  Perineural invasion by prostate cancer on MR/US fusion targeted biopsy is associated with extraprostatic extension and early biochemical recurrence after radical prostatectomy. , 2017, Human pathology.

[20]  P. Humphrey,et al.  Negative Multiparametric Magnetic Resonance Imaging of the Prostate Predicts Absence of Clinically Significant Prostate Cancer on 12-Core Template Prostate Biopsy. , 2017, Urology.

[21]  S. Rais-Bahrami,et al.  Factors predicting prostate cancer upgrading on magnetic resonance imaging–targeted biopsy in an active surveillance population , 2017, Cancer.

[22]  M. Parmar,et al.  Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confi rmatory study , 2018 .

[23]  P. Pepe,et al.  Transperineal Versus Transrectal MRI/TRUS Fusion Targeted Biopsy: Detection Rate of Clinically Significant Prostate Cancer , 2017, Clinical genitourinary cancer.

[24]  S. Das,et al.  Developing a new PI-RADS v2-based nomogram for forecasting high-grade prostate cancer. , 2017, Clinical radiology.

[25]  D. Georg,et al.  Head-to-head comparison of PI-RADS v2 and PI-RADS v1. , 2016, European journal of radiology.

[26]  Baris Turkbey,et al.  Clinical implications of a multiparametric magnetic resonance imaging based nomogram applied to prostate cancer active surveillance. , 2015, The Journal of urology.

[27]  B. Turkbey,et al.  Multiparametric magnetic resonance imaging outperforms the Prostate Cancer Prevention Trial risk calculator in predicting clinically significant prostate cancer , 2014, Cancer.

[28]  Baris Turkbey,et al.  Comparison of endorectal coil and nonendorectal coil T2W and diffusion‐weighted MRI at 3 Tesla for localizing prostate cancer: Correlation with whole‐mount histopathology , 2014, Journal of magnetic resonance imaging : JMRI.

[29]  P. Choyke,et al.  Utility of multiparametric magnetic resonance imaging suspicion levels for detecting prostate cancer. , 2013, The Journal of urology.

[30]  Mohammad Hassan Murad,et al.  Early detection of prostate cancer: AUA Guideline. , 2013, The Journal of urology.

[31]  E. Steyerberg,et al.  Prediction of prostate cancer risk: the role of prostate volume and digital rectal examination in the ERSPC risk calculators. , 2012, European urology.

[32]  D. Koulikov,et al.  Why I Cannot Find the Prostate? Behind the Subjectivity of Rectal Exam , 2012, ISRN urology.

[33]  Ziding Feng,et al.  Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. , 2006, Journal of the National Cancer Institute.